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Abstract
Background: Early detection or notification of adverse event (AE) occurrences during clinical trials is essential to ensure patient
safety. Clinical trials take advantage of innovative strategies, clinical designs, and state-of-the-art technologies to evaluate efficacy
and safety, however, early awareness of AE occurrences by investigators still needs to be systematically improved.
Objective: This study aimed to build a system to promptly inform investigators when clinical trial participants make unscheduled
visits to the emergency room or other departments within the hospital.
Methods: We developed the Adverse Event Awareness System (AEAS), which promptly informs investigators and study
coordinators of AE occurrences by automatically sending text messages when study participants make unscheduled visits to the
emergency department or other clinics at our center. We established the AEAS in July 2015 in the clinical trial management
system. We compared the AE reporting timeline data of 305 AE occurrences from 74 clinical trials between the preinitiative
period (December 2014-June 2015) and the postinitiative period (July 2015-June 2016) in terms of three AE awareness performance
indicators: onset to awareness, awareness to reporting, and onset to reporting.
Results: A total of 305 initial AE reports from 74 clinical trials were included. All three AE awareness performance indicators
were significantly lower in the postinitiative period. Specifically, the onset-to-reporting times were significantly shorter in the
postinitiative period (median 1 day [IQR 0-1], mean rank 140.04 [SD 75.35]) than in the preinitiative period (median 1 day [IQR
0-4], mean rank 173.82 [SD 91.07], P≤.001). In the phase subgroup analysis, the awareness-to-reporting and onset-to-reporting
indicators of phase 1 studies were significantly lower in the postinitiative than in the preinitiative period (preinitiative: median 1
day, mean rank of awareness to reporting 47.94, vs postinitiative: median 0 days, mean rank of awareness to reporting 35.75,
P=.01; and preinitiative: median 1 day, mean rank of onset to reporting 47.4, vs postinitiative: median 1 day, mean rank of onset
to reporting 35.99, P=.03). The risk-level subgroup analysis found that the onset-to-reporting time for low- and high-risk studies
significantly decreased postinitiative (preinitiative: median 4 days, mean rank of low-risk studies 18.73, vs postinitiative: median
1 day, mean rank of low-risk studies 11.76, P=.02; and preinitiative: median 1 day, mean rank of high-risk studies 117.36, vs
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postinitiative: median 1 day, mean rank of high-risk studies 97.27, P=.01). In particular, onset to reporting was reduced more in
the low-risk trial than in the high-risk trial (low-risk: median 4-0 days, vs high-risk: median 1-1 day).
Conclusions: We demonstrated that a real-time automatic alert system can effectively improve safety reporting timelines. The
improvements were prominent in phase 1 and in low- and high-risk clinical trials. These findings suggest that an information
technology-driven automatic alert system effectively improves safety reporting timelines, which may enhance patient safety.
(JMIR Med Inform 2020;8(2):e14379)  doi: 10.2196/14379
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Introduction
In recent trends of drug development, proof of concept is rapidly
achieved at a low cost, allowing successful projects to be
promptly positioned for late-stage development [1,2]; thus, it
is critical that investigators be notified of the early signs of a
drug’s efficacy and safety in real time during clinical trials. The
solutions to the challenges of postmarketing evaluation of drug
safety require highly collaborative interactions among the US
Food and Drug Administration, industry, and other health
authorities, as well as the development of registries for
spontaneous reporting and epidemiological statistical
methodology to detect and interpret adverse event (AE) signals
[3-6]. Although clinical trials have rigorous procedures for
reporting AEs, few studies have investigated how to detect and
report them [7-9].
For reporting, the Consolidated Standards of Reporting Trials
(CONSORT) Group generated recommendations regarding the
appropriate reporting of AEs [8,9]. With advances in information
technology (IT), the reporting of safety and other clinical trial
data is moving from paper-based to electronic formats.
Typically, electronic reporting portals developed by the clinical
trial sponsors and contract research organizations are used as
centralized electronic repositories for ongoing clinical trial
information to reduce time and cost associated with
recordkeeping.
To ensure the safety of study participants, it is crucial to
promptly manage AEs and serious adverse events (SAEs),
especially during high-risk or early-phase clinical trials. AE
management consists of detection, processing, and reporting.
AEs in clinical trials are usually detected during scheduled visits
or when participants inform investigators of unscheduled visits
to the emergency department or clinic. Unscheduled visits are
sometimes detected by coordinators during the review of
patients’ electronic health records. Delayed awareness of AEs
among study personnel may jeopardize patient safety, so the
prompt detection of unscheduled visits is important during
clinical trials. While many health care practitioners understand
the importance of AE awareness and reporting in the clinical
trial field, they face practical hurdles in systematically managing
AEs.
To build a systematic AE management process that addresses
issues from occurrence to awareness and reporting, IT support
with clinical trial management systems (CTMSs) and electronic
medical records (EMRs) can be useful. In July 2015, we
established an alert system called the Adverse Event Awareness
System (AEAS), which was derived from CTMSs and EMRs
[10,11]. The AEAS promptly informs investigators when clinical
trial participants make unscheduled visits to the emergency
room or other departments within the hospital. Such notifications
were designed to improve the timelines of AE reporting to
stakeholders, such as sponsors, institutional review boards
(IRBs), or regulatory bodies. This study investigated the
effectiveness of the AEAS by analyzing and comparing the
relevant AE reporting timelines before and after the
establishment of the AEAS.
Methods
Study Setting
This study was conducted at Asan Medical Center (AMC), a
tertiary hospital in Seoul, South Korea. AMC is the largest
medical center in Korea, with approximately 2700 inpatient
beds and 10,000 outpatient visits per day. AMC has been fully
accredited by the Association for the Accreditation of Human
Research Protection Program since 2013; the IRB at AMC has
received accreditation from the Forum for Ethical Review
Committees in the Asian and Western Pacific Region since
2006.
In the process of clinical trials, AMC follows the US Food and
Drug Administration regulations, as well as the Korean Good
Clinical Practice and International Conference on Harmonization
guidelines for AE reporting, which stipulate that all SAEs must
be immediately reported to the sponsor except for those that the
protocol or Investigator’s Brochure identifies as not requiring
immediate reporting [12,13]. Sponsors are also required to report
fatal and life-threatening suspected unexpected serious reactions
(SUSARs) to regulatory agencies within 7 days after the
sponsor’s initial receipt of the information, while other SUSARs
may be reported within 15 days.
To manage clinical trials, we implemented a site-specific CTMS
in December 2014 [10]. A CTMS is a system for managing
clinical trials and research data. The requirements of various
organizations related to clinical trials were developed for 14
months and implemented for 12 months based on the Java-based
Spring Framework 4.0 (Pivotal Software). The CTMS was
developed as an all-in-one system that links hospital information
systems, the electronic IRB, enterprise resource planning, and
biomaterial management systems in the respective academic
medical center. The AEAS was implemented in July 2015 as a
submodule of the CTMS interfaced with the EMR to facilitate
early awareness of AE occurrences by investigators and study
coordinators. The detailed operation process is as follows: if a
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patient makes an unscheduled visit to the hospital, the EMR
confirms that the patient is in a clinical trial; if the patient
participates in a specific clinical trial, the patient’s information
is sent to the CTMS through the application programming
interface; the CTMS then sends a text notification to the
principal investigator or clinical research coordinator regarding
the patient’s emergency room visit or hospitalization.
Selection of Clinical Trials
From December 2014 to June 2016, 196 clinical trials were
managed through the AMC CTMS. Among these trials, 93 had
at least one AE report, with a total of 305 initial, 403 follow-up,
and 179 finalized AE reports. In this study, we included 305
initial AE reports from 74 clinical trials to measure the
improvement in AE awareness by the implementation of the
AEAS. The follow-up or finalized reports were excluded from
this study because they could not serve to verify the
effectiveness of the AEAS in matters such as early recognition
of AEs.
A total of 117 initial AEs were processed in the CTMS prior to
the implementation of the AEAS—December 2014 to June
2015—and 188 initial AEs were processed
postimplementation—July 2015 to June 2016 (see Figure 1).
Overall, patient AE monitoring processes were the same in the
pre- and postinitiative periods, but the AE awareness method
was different: people-dependent versus system-supported. Of
the 74 clinical trials that were evaluated, 41 were carried out
during the preinitiative period and 53 during the postinitiative
period, with 20 trials overlapping the two periods.
The following data were collected: the dates of initial AE onset
when investigators became aware of a given AE and when the
AE report was submitted. The intervals between each step were
calculated, with AE onset defined as the time when patients
made an unscheduled visit to the emergency room or clinics.
Figure 1. Initial adverse event (AE) reports before and after implementation of the Adverse Event Awareness System (AEAS). CTMS: clinical trial
management system; EMR: electronic medical record.
Statistical Analysis
General characteristics were compared using chi-square tests.
The numbers of days between AE reporting phases (ie, onset,
awareness, and reporting) were presented as medians with IQRs
and mean ranks with SDs among the periods before and after
AEAS implementation. The Shapiro-Wilk normality test showed
the time intervals between AE onset, awareness, and reporting
to have nonnormal distributions. We, therefore, used the
Wilcoxon rank-sum test for comparing the pre- and postinitiative
periods. We also presented the effect size of a pre- and
postcomparison with a Cohen d test. According to US Food and
Drug Administration guidelines, AEs are reported as being on
business days [14-16]; likewise, we set the intervals using
business days. We also performed subgroup analyses according
to risk level and study phase. The risk level of each clinical trial
was determined based on the classification by the ADApted
MONitoring (ADAMON) project [17]. A higher risk level value
means a subject has a higher than lower risk level. P values
lower than .05 were deemed statistically significant. All analyses
were performed in R, version 3.5.3 (The R Foundation).
Ethics Statement
This study was approved by the IRB of AMC (IRB No.
2015-1368). The need for informed consent was waived by the
ethics committee on the basis that this study utilized routinely
collected medical data that were anonymously managed at all
stages, including data cleaning and statistical analyses.
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A total of 305 initial AE reports from 74 clinical trials were
included in this study (see Table 1). Most initial AE reports
subjected to analysis occurred in sponsor-initiated trials
(286/305, 93.8%) and multisite trials (273/305, 89.5%). Initial
AE reports were more common in phase 3 trials, followed by
phase 1 and 2 trials; approximately 70% of initial AE reports
were from risk-level 3 trials (210/305, 68.9%). Most of the basic
characteristics of the clinical trials were not significantly
different between the pre- and postinitiative periods. The
frequency of global trials was higher in the postinitiative period.
Table 1. Basic characteristics of initial adverse event (AE) reports from 74 clinical trials.
P valueaPostinitiative (N=188), n (%)Preinitiative (N=117), n (%)Total (N=305), n (%)Category
.46Type of clinical trial
10 (5.3)9 (7.6)19 (6.2)Investigator-initiated trial
177 (94.7)109 (92.4)286 (93.8)Sponsor-initiated trial
.06Number of sites involved
163 (87.2)110 (93.2)273 (89.5)Multisite
25 (13.4)7 (5.9)32 (10.5)Single site
.08Phase
54 (28.9)24 (20.3)78 (25.6)1
30 (16.0)26 (22.0)56 (18.4)2
84 (44.9)33 (28.0)117 (38.4)3
20 (10.7)34 (28.8)54 (17.7)4 and other
.009Scope of trial
21 (11.2)27 (22.9)48 (15.7)Domestic
167 (89.3)90 (76.3)257 (84.3)Global
.32Risk level
17 (9.1)11 (9.3)28 (9.2)1
47 (25.1)20 (16.9)67 (22.0)2
124 (66.3)86 (72.9)210 (68.9)3
53 (28.3)41 (34.7)74 (24.3)Number of clinical trials
aChi-square test.
Adverse Event Awareness Performance
All three AE awareness performance indicators were
significantly lower in the postinitiative phase (see Table 2 and
Figure 2). However, due to the skewed distribution (see Figure
2), median values were 0 days in both the pre- and postinitiative
phases. Statistical testing found the distributions to be
significantly lower, and examination of the mean rank
demonstrated that reporting times were lower and more
consistent overall in the postinitiative phase. In particular, the
onset to reporting showed a statistically significant difference
(preinitiative: median 1 day, mean rank 173.82, vs postinitiative:
median 1 day, mean rank 140.04, P<.001). The
onset-to-awareness and awareness-to-reporting time also showed
significant reductions between the pre- and postinitiative periods
(preinitiative: median 0 days, mean rank 164.15, vs
postinitiative: median 0 days, mean rank 146.06, P=.04; and
preinitiative: median 1 day, mean rank 173.82, vs postinitiative:
median 1 day, mean rank 140.04, P=.02, respectively).
Figure 2 shows the date difference between pre- and
postinitiatives by three AE awareness indicators. For all three
AE awareness indicators, the phenomenon of AE records taking
more than 25 business days preinitiative disappeared
postinitiative.
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Table 2. Adverse event (AE) awareness efficiency, preinitiative and postinitiative.
Effect
sizeb
P valueaPostinitiative (N=188 AEs)Preinitiative (N=118 AEs)AE awareness performance indicator
Mean rank (SD)Business days, me-
dian (IQR)
Mean rank (SD)Business days, median
(IQR)
0.117.04146.06 (68.67)0 (0-1)164.15 (83.41)0 (0-2)Onset to awareness
0.135.02145.25 (67.36)0 (0-1)165.45 (79.58)0 (0-1)Awareness to reporting
0.197<.001140.04 (75.35)1 (0-1)173.82 (91.07)1 (0-4)Onset to reporting
aWilcoxon rank-sum test.
bEffect sizes—0.1 (small effect), 0.3 (moderate effect), and 0.5 and above (large effect)—were calculated by dividing the absolute standardized test
statistic z by the square root of the number of pairs.
Figure 2. Date difference comparison between preinitiative (pre) and postinitiative (post) periods by adverse event (AE) awareness performance
indicators.
Adverse Event Awareness Performance by Phase and
Risk
The phase subgroup analysis showed that all AE awareness
indicators were reduced from the preinitiative period (see Table
3). The awareness-to-reporting and onset-to-reporting indicators
in phase 1 studies showed statistically significant differences
in median values and mean rank pre- and postinitiative
(preinitiative: median 1 day, mean rank 47.94, vs postinitiative:
median 0 days, mean rank 35.75, P=.01; and preinitiative:
median 1 day, mean rank 47.4, vs postinitiative: median 1 day,
mean rank 35.99, P=.03, respectively). In phase 4, there was
no statistically significant difference in the onset-to-reporting
timeline, but the SD of postinitiative ranks was significantly
smaller than that of preinitiative ranks (preinitiative: rank SD
16.41 vs postinitiative: rank SD 11.89). Phase 3 and 4 studies
showed greater differences than did phase 1 and 2 studies in the
pre- and postinitiative SD values of all AE awareness
performance indicators.
In the risk-level subgroup analysis, decreases of all AE report
timelines were observed between pre- and postinitiative periods
(see Table 4). Onset to awareness and onset to reporting of
low-risk trials (level 1) showed significant reductions in the
median and mean rank (preinitiative: median 4 days, mean rank
18.91, vs postinitiative: median 0 days, mean rank 11.65, P=.02;
and preinitiative: median 4 days, mean rank 18.73, vs
postinitiative: median 1 day, mean rank 11.76, P=.02,
respectively). In high-risk trials (level 3), the distributions of
awareness to reporting and onset to reporting were significantly
different pre- and postinitiative (preinitiative: median 0 days,
mean rank 115.94, vs postinitiative: median 0 days, mean rank
98.26, P=.02; and preinitiative: median 1 day, mean rank 117.36,
vs postinitiative: median 1 day, mean rank 97.27, P=.01,
respectively).
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Table 3. Adverse event (AE) awareness efficiency, preinitiative and postinitiative, by study phase.
Effect
sizeb
P valueaPostinitiativePreinitiativeAE awareness perfor-
mance indicator by phase
Number of
records








Phase 1 (n=22 studies, n=78 AEs)
0.09.415438.37 (17.04)0 (0-0.75)2442.04
(19.86)
0 (0-1)Onset to awareness
0.28.0135.75 (18.55)0 (0-1)47.94
(20.61)




1 (0.75-2.50)Onset to reporting
Phase 2 (n=14 studies, n=56 AEs)
0.01.943028.35 (13.65)0.5 (0-1)2628.67
(16.42)
0 (0-1.75)Onset to awareness
0.17.2126.17 (13.78)0 (0-1)31.19
(15.85)




1.5 (0.25-4.75)Onset to reporting
Phase 3 (n=29 studies, n=117 AEs)
0.04.638458.22 (26.28)0 (0-1)3360.98
(31.18)
0 (0-1)Onset to awareness
0.05.5758.17 (24.54)0 (0-0)61.12
(26.84)




0 (0-1)Onset to reporting
Phase 4 and other (n=9 studies, n=54 AEs)
0.20.152023.80 (12.03)0 (0-1)3429.68
(15.20)
0.5 (0-3.75)Onset to awareness
0.02.8727.13 (10.88)0 (0-0.25)27.72
(12.41)




1 (0-6.75)Onset to reporting
aWilcoxon rank-sum test.
bEffect sizes—0.1 (small effect), 0.3 (moderate effect), and 0.5 and above (large effect)—were calculated by dividing the absolute standardized test
statistic z by the square root of the number of pairs.
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Table 4. Adverse event (AE) awareness efficiency in preinitiative and postinitiative periods according to risk level.
Effect
sizeb
P valueaPostinitiativePreinitiativeAE awareness performance
indicator by risk level
Number
of records




Mean rank (SD)Business days,
median (IQR)
Level 1 (n=5 studies, n=28 AEs)
0.46.021711.65 (5.99)0 (0-1)1118.91 (8.09)4 (0.5-22.0)Onset to awareness
0.03.8714.68 (5.90)0 (0-0)14.23 (6.10)0 (0-0)Awareness to reporting
0.43.0211.76 (6.30)1 (0-1)18.73 (8.35)4 (1-23)Onset to reporting
Level 2 (n=17 studies, n=67 AEs)
0.22.084731.55 (15.27)0 (0-1)2039.75 (20.31)0.5 (0-6.25)Onset to awareness
0.01.9234.12 (12.54)0 (0-0)33.73 (12.80)0 (0-0)Awareness to reporting
0.13.2832.45 (16.00)1 (0-1)37.65 (21.93)0.5 (0-6.25)Onset to reporting
Level 3 (n=52 studies, n=210 AEs)
0.05.52124103.63 (47.69)0 (0-1)86108.20 (53.50)0 (0-1)Onset to awareness
0.16.0298.26 (48.93)0 (0-1)115.94 (56.72)0 (0-1)Awareness to reporting
0.17.0197.27 (53.62)1 (0-1)117.36 (61.19)1 (0-3)Onset to reporting
aWilcoxon rank-sum test.
bEffect sizes—0.1 (small effect), 0.3 (moderate effect), and 0.5 and above (large effect)—were calculated by dividing the absolute standardized test
statistic z by the square root of the number of pairs.
Discussion
Principal Findings
The most notable finding of this study is that the timeline from
patients’ unscheduled visits (ie, onset), due to AE, to safety
reporting was significantly reduced after the implementation of
the AEAS. Also, the variability in the amount of time between
patient visits and investigator awareness was lower after the
implementation. This suggests that the AEAS notifications are
effective for improving the speed with which investigators or
clinical research coordinators are informed, thereby allowing
them to take prompt action against AE occurrences.
There have been several approaches to enhance the efficiency,
completeness, and consistency of safety reporting through the
use of Web-based electronic safety reporting modules [18,19].
However, such approaches do not detect patients’ unscheduled
visits at the site level. To our knowledge, this is the first study
to evaluate the effectiveness of the implementation of an
IT-driven AE awareness system for clinical trials at the site
level. Early safety signal awareness with the alert system may
contribute to better patient protection after the occurrence of
AEs. A recent study found that many SAE results registered in
ClinicalTrials.gov were yet to be published or omitted from
publications [20]. Due to the imbalance of information on AE
reporting, there is a high demand for more comprehensive
approaches to ensure the safety of clinical trial participants
[20-22]. There are only a few reports that have evaluated the
timeline between AE onset and the initial reporting of the AE
at the site level. One study reported that the mean duration from
onset to reporting was 25 days for nonserious AEs and 11 days
for SAEs [18]. However, to the best of our knowledge, there
are no reports on other systems designed to improve the
detection of AEs during clinical trials. Caution is necessary
when comparing our findings with those of other studies because
of the differences in protocols, safety reporting systems, and
sites. However, our improved safety reporting metrics—from
unscheduled visit to reporting—which were less than 2 days in
the postinitiative period, deserve highlighting.
Another interesting finding is that the improvement in
turnaround times after AEAS implementation was more
prominent in phase 1 and in low- and high-risk clinical trials.
The primary goal of a phase 1 study is to identify safety profiles
and determine the dose-limiting toxicities of a new drug. This
might be due to the increased attention being paid to participants
in phase 1; therefore, the improvement in the reporting timeline
was not as noticeable in trials of other phases as it was in phase
1 trials. We note that the safety reporting timeline is shorter
postinitiative than preinitiative in all phases of clinical research.
Limitations
The main limitation of our study is that our study results are
based on a retrospective analysis of clinical trials carried out in
a single academic medical center. Also, this system could not
detect patient visits to other hospitals, which would require
patient self-reporting; the rate of patient self-reporting may be
improved with education, telephone monitoring, and questioning
during trial visits. Another limitation is that we only analyzed
the timeline for reporting AEs. Nevertheless, detailed analyses
of AEs in clinical trials were not accessible at this point, as such
analysis is only possible when the data are reported to the
regulatory agency and published. Due to the study’s
retrospective nature, there is a trend of imbalances among
several characteristics, such as phase of trial or number of sites.
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In this study, we demonstrated that the AEAS, a CTMS-driven
real-time automatic alert system, can effectively improve safety
reporting timelines. The AEAS resulted in overall reductions
in AE awareness timelines in all clinical trials, especially in
phase 1 trials and low- and high-risk studies. These findings
suggest that IT-driven automatic alert systems are effective in
improving safety reporting timelines, which may ultimately
enhance patient safety.
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